Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Marcelin AG, Lamotte C, Delaugerre C, Ktorza N, Ait Mohand H, Cacace R, Bonmarchand M, Wirden M, Simon A, Bossi P, Bricaire F, Costagliola D, Katlama C, Peytavin G, Calvez V; Genophar Study Group. Marcelin AG, et al. Among authors: ktorza n. Antimicrob Agents Chemother. 2003 Feb;47(2):594-600. doi: 10.1128/AAC.47.2.594-600.2003. Antimicrob Agents Chemother. 2003. PMID: 12543665 Free PMC article. Clinical Trial.
Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.
Wirden M, Delaugerre C, Marcelin AG, Ktorza N, Ait Mohand H, Dominguez S, Schneider L, Ghosn J, Pauchard M, Costagliola D, Katlama C, Calvez V. Wirden M, et al. Among authors: ktorza n. Antimicrob Agents Chemother. 2004 Feb;48(2):644-7. doi: 10.1128/AAC.48.2.644-647.2004. Antimicrob Agents Chemother. 2004. PMID: 14742228 Free PMC article. Clinical Trial.
GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.
Bossi P, Peytavin G, Ait-Mohand H, Delaugerre C, Ktorza N, Paris L, Bonmarchand M, Cacace R, David DJ, Simon A, Lamotte C, Marcelin AG, Calvez V, Bricaire F, Costagliola D, Katlama C. Bossi P, et al. Among authors: ktorza n. HIV Med. 2004 Sep;5(5):352-9. doi: 10.1111/j.1468-1293.2004.00234.x. HIV Med. 2004. PMID: 15369510 Free article. Clinical Trial.
Pitfalls of HIV genotypic tropism testing after treatment interruption.
Wirden M, Soulié C, Fourati S, Valantin MA, Simon A, Ktorza N, Tubiana R, Bonmarchand M, Schneider L, Calvez V, Katlama C, Marcelin AG. Wirden M, et al. Among authors: ktorza n. J Antimicrob Chemother. 2013 Jan;68(1):188-9. doi: 10.1093/jac/dks362. Epub 2012 Sep 6. J Antimicrob Chemother. 2013. PMID: 22954492
Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra study.
Schneider L, Ktorza N, Fourati S, Assoumou L, Courbon E, Caby F, Blanc C, Tindel M, Agher R, Marcelin AG, Calvez V, Peytavin G, Katlama C. Schneider L, et al. Among authors: ktorza n. HIV Clin Trials. 2012 Sep-Oct;13(5):284-8. doi: 10.1310/hct1305-284. HIV Clin Trials. 2012. PMID: 23134629 Clinical Trial.
21 results